

| PA Criteria | Criteria Details | | | | | | |
|---|---|---|-------------|----------------------------|-------|---|---|
| Covered Uses (FDA approved indication) | Stelara is a monoclonal antibody that inhibits interleukin (IL)-12 and IL-23 and is an IL-17 receptor A antagonist indicated for several inflammatory conditions including Plaque Psoriasis (PsO), Psoriatic Arthritis (PsA), Ulcerative Colitis (UC) and Crohn's Disease (CD). | | | | | | |
| Exclusion Criteria | Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis). | | | | | | |
| Required Medical Information | Medical records supporting the request must be provided, including documentation of prior therapies and responses to treatment. Patient's current weight must be provided. | | | | | | |
| Age Restriction | None. | | | | | | |
| Prescriber Restrictions | Prescriber is a specialist or has consulted with a specialist for the condition being treated. | | | | | | |
| Coverage Duration | One-time induction dose. Doses are approved according to the FDA-approved labeling or within accepted standards of medical practice. | | | | | | |
| Other Criteria/Information | Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document. <table border="1" data-bbox="500 989 1511 1136"> <thead> <tr> <th>HCPCS</th> <th>Description</th> <th>Billing Units/How Supplied</th> </tr> </thead> <tbody> <tr> <td>J3358</td> <td>Stelara IV (ustekinumab) 130mg/26ml vial</td> <td>Billing unit: 1 mg 130 mg/26 mL SDV</td> </tr> </tbody> </table> | HCPCS | Description | Billing Units/How Supplied | J3358 | Stelara IV (ustekinumab) 130mg/26ml vial | Billing unit: 1 mg 130 mg/26 mL SDV |
| HCPCS | Description | Billing Units/How Supplied | | | | | |
| J3358 | Stelara IV (ustekinumab) 130mg/26ml vial | Billing unit: 1 mg 130 mg/26 mL SDV | | | | | |

| STATUS | DATE REVISED | REVIEW DATE | APPROVED/REVIEWED BY | EFFECTIVE DATE |
|----------|--------------|-------------|---|----------------|
| Created | 3/26/2025 | 3/26/2025 | Dawn Shojai, PharmD, Senior Pharmacy Benefit Consultant (PSG) | N/A |
| Approved | N/A | 5/15/2025 | Pharmacy & Therapeutics (P&T) Committee | 5/15/2025 |
| | | | | |
| | | | | |